ICU Medical (NASDAQ:ICUI) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

ICU Medical, Inc. (NASDAQ:ICUI)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $157.00 and traded as high as $162.01. ICU Medical shares last traded at $160.99, with a volume of 133,187 shares traded.

Wall Street Analyst Weigh In

Several analysts have commented on ICUI shares. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Raymond James upped their price objective on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and a consensus target price of $199.67.

ICU Medical Trading Down 0.7 %

The stock has a market cap of $3.94 billion, a PE ratio of -35.23 and a beta of 0.63. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company has a 50 day moving average of $163.34 and a two-hundred day moving average of $157.00.

Insider Activity

In other news, COO Christian B. Voigtlander sold 1,430 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total value of $225,940.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,973,261.12. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,737 shares of company stock worth $4,941,832 over the last three months. 6.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hexagon Capital Partners LLC lifted its stake in shares of ICU Medical by 162.7% in the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares in the last quarter. Allworth Financial LP grew its position in shares of ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares in the last quarter. Venturi Wealth Management LLC increased its holdings in shares of ICU Medical by 1,510.0% in the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in ICU Medical during the second quarter worth approximately $70,000. Finally, Canada Pension Plan Investment Board acquired a new position in ICU Medical during the second quarter worth $71,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.